CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

NCT ID: NCT04034446

Last Updated: 2025-06-03

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-30
• Study Completion Date: 2020-12-01

Brief Summary

This is a single arm, open-label, single center study to determine the safety and efficacy of CD19-CD22 CAR-T cells in patients with CD19+CD22+ Leukemia.

Detailed Description

This is a single arm, open-label, single center study to determine the safety and efficacy of CD19-CD22 CAR-T cells in patients with relapsed or refractory B-ALL. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Follow-up, and Survival Follow-up. The total duration of the study is 2 years from CD19-CD22 CAR-T cell infusion.

Conditions

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

Single dose of CD19-CD22 CAR-T cells

Group Type: EXPERIMENTAL

CD19-CD22 CAR-T cells

Intervention Type: BIOLOGICAL

0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.

Interventions

CD19-CD22 CAR-T cells

0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Informed consent is signed by a subject or his lineal relation.

2. Age 3 and older.

3. Documentation of cluster of differentiation 19 (CD19) and or cluster of differentiation 19 (CD22) expression on leukemic blasts in the BM, peripheral blood within 3 months of screening.;

4. Relapsed or refractory B-cell ALL

• Relapse within 12 months of first remission
• Without remission after 2 cycles of induction chemotherapy regimen.
• Without remission or relapse after salvage treatments.
• Any BM relapse after autologous stem cell transplantation (ASCT).

5. Without remission or relapse after any prior CD19 targeted therapy;

6. Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they are intolerant to or have failed 2 lines of tyrosine kinase inhibitor therapy (TKI); no TKI salvage treatments if the patient has a BCR-ABL1 kinase domain gatekeeper mutation Thr315Ile (T315I) mutation.

7. Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening；

8. Eastern cooperative oncology group (ECOG) performance status of 0 to 2.

9. Adequate organ function defined as:

• Aspartate aminotransferase (AST) ≤3 upper limit of normal (ULN);
• Serum alanine aminotransferase (ALT) ≤3 ULN;
• Total bilirubin ≤ 2 ULN, except in individuals with Gilbert's syndrome;
• Note: Patients with Gilbert's syndrome that bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN will be eligible.
• A serum creatinine≤ 1.5 ULN or Creatine removal rate ≥ 60mL/min（Cockcroft and Gault）
• Must have a minimum level of pulmonary reserve as ≤ Grade 1 dyspnea and oxygen saturation > 91% on room air.
• Absolute lymphocyte count ≥0.3 x 10⁹/L.

10. Women of child-bearing potential and all male participants must use highly effective methods of contraception for a period of 1 year after the CD19-CD22 CAR-T cells infusion.

Exclusion Criteria

1. Active central nervous system leukemia

2. Patients with evidence of currently uncontrollable serious active infections (e.g., sepsis, bacteremia, fungemia, viremia, etc.).

3. Patients who are positive for any of HIV antibody, TP antibody, hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) antibody.

4. Major surgery within ≤ 4 weeks before enrollment.

5. Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent.

6. Impaired cardiac function:

• Left Ventricular Ejection Fraction (LVEF) ≤45%;
• III/IV congestive heart failure (NYHA);
• Severe arrhythmia (except for Atrial fibrillation, Paroxysmal supraventricular tachycardia);
• Corrected QT interval (QTc) ≥450ms (male) or QTc≥470ms (female)（QTc using Bazett's formula (QTcB)=QT/RR^0.5）;
• Myocardial infarction or Coronary Artery Bypass Graft Surgery, heart stent surgery.
• Other heart diseases that have been judged by the investigator to be unsuitable for receiving cell therapy.

7. Patients with a history of epilepsy or other active central nervous system diseases.

8. Life expectancy < 12 weeks.

9. Allergy to macromolecule biopharmaceuticals such as antibodies or cytokines.

10. Subjects who are receiving systemic steroid treatment and who have been determined by the researchers to require long-term treatment with systemic steroids during treatment, and subjects treated with systemic steroids must be excluded < 72 hours prior to CNCT19 infusion (except inhalation or local use).

11. Patients with other conditions making the patients unsuitable for receiving cell therapy as judged by the investigator.

• Minimum Eligible Age: 3 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Juventas Cell Therapy Ltd.

INDUSTRY

Sponsor Role: collaborator

Institute of Hematology & Blood Diseases Hospital, China

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Institute of Hematology & Blood Diseases Hospital

Tianjin, , China

Countries

China

Other Identifiers

QT2019005

Identifier Type: -

Identifier Source: org_study_id